English  |  正體中文  |  简体中文  |  Post-Print筆數 : 11 |  Items with full text/Total items : 88657/118248 (75%)
Visitors : 23503861      Online Users : 182
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    政大機構典藏 > 理學院 > 心理學系 > 期刊論文 >  Item 140.119/75233
    Please use this identifier to cite or link to this item: http://nccur.lib.nccu.edu.tw/handle/140.119/75233


    Title: Hepatitis B viral factors and treatment responses in chronic hepatitis B
    Authors: Lin, Chih-Lin
    林志陵
    Kao, J.-H.
    Contributors: 心理系
    Keywords: adefovir;adefovir dipivoxil;alanine aminotransferase;alpha interferon;creatinine;entecavir;hepatitis B surface antigen;lamivudine;peginterferon alpha;peginterferon alpha2a;peginterferon alpha2b;telbivudine;tenofovir disoproxil;virus DNA;antiviral resistance;antiviral therapy;clinical effectiveness;competitive inhibition;creatinine blood level;disease association;disease exacerbation;drug efficacy;drug half life;genotype;hepatitis B;Hepatitis B virus;human;liver cirrhosis;monotherapy;mutational analysis;nephrotoxicity;predictive value;review;risk factor;seroconversion;side effect;treatment duration;treatment response;viremia;virus strain;Antiviral Agents;DNA, Viral;Hepatitis B e Antigens;Hepatitis B Surface Antigens;Hepatitis B virus;Hepatitis B, Chronic;Humans;Interferon-alpha;Lamivudine;Polyethylene Glycols;Recombinant Proteins
    Date: 2013-06
    Issue Date: 2015-05-21 16:24:11 (UTC+8)
    Abstract: Baseline and on-treatment hepatitis B viral factors are reported to affect treatment responses. A lower baseline hepatitis B virus (HBV) DNA level is a strong predictor of the response to antiviral therapy. HBV genotype A/B patients have better responses to interferon-based therapy than those with genotypes C/D. Regarding the association of HBV mutants with responses to antiviral therapy, current evidence is limited. On-treatment viral suppression is the most important predictor of response to nucleoside analogs. On-treatment hepatitis B surface antigen decline is significantly associated with response to pegylated interferon. In the future, individualized therapy should be based on treatment efficacy, adverse effects, baseline and on-treatment predictors of antiviral therapy. © 2012, Elsevier Taiwan LLC & Formosan Medical Association.
    Relation: Journal of the Formosan Medical Association, 112(6), 302-311
    Data Type: article
    DOI 連結: http://dx.doi.org/10.1016/j.jfma.2013.02.001
    DOI: 10.1016/j.jfma.2013.02.001
    Appears in Collections:[心理學系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    302-311.pdf334KbAdobe PDF565View/Open


    All items in 政大典藏 are protected by copyright, with all rights reserved.


    社群 sharing

    著作權政策宣告
    1.本網站之數位內容為國立政治大學所收錄之機構典藏,無償提供學術研究與公眾教育等公益性使用,惟仍請適度,合理使用本網站之內容,以尊重著作權人之權益。商業上之利用,則請先取得著作權人之授權。
    2.本網站之製作,已盡力防止侵害著作權人之權益,如仍發現本網站之數位內容有侵害著作權人權益情事者,請權利人通知本網站維護人員(nccur@nccu.edu.tw),維護人員將立即採取移除該數位著作等補救措施。
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback